Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Piotroski F-Score: 4 (As of Jul. 28, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2TZ Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
72 GF Score
Price €2.44
GF Value €1.64
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Piotroski F-Score?

Tianjin Pharmaceutical Da Ren Tang Group STU:2TZ +1.67% 72 Piotroski F-Score is 4 as of Jul. 28, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates STU:2TZ with a GF Score™ of 72/100 and a GF Value™ of €1.64 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Tianjin Pharmaceutical Da Ren Tang Group ranks worse than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin Pharmaceutical Da Ren Tang Group has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score or its related term are showing as below:

STU:2TZ' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Tianjin Pharmaceutical Da Ren Tang Group was 8. The lowest was 2. And the median was 6.

Tianjin Pharmaceutical Da Ren Tang Group  (STU:2TZ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Tianjin Pharmaceutical Da Ren Tang Group Piotroski F-Score Related Terms


Tianjin Pharmaceutical Da Ren Tang Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group Piotroski F-Score Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 5.00 5.00 6.00 4.00

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 7.00 4.00 4.00

STU:2TZ vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score falls into.


STU:2TZ
72GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 187.563 + 26.858 + -2.566 + 53.19 = €265.0 Mil.
Cash Flow from Operations was 15.964 + 12.27 + -15.673 + 52.985 = €65.5 Mil.
Revenue was 144.317 + 121.918 + 151.258 + 190.167 = €607.7 Mil.
Gross Profit was 109.2 + 92.401 + 107.69 + 147.773 = €457.1 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1425.004 + 1551.996 + 1385.633 + 1417.4 + 1309.745) / 5 = €1417.9556 Mil.
Total Assets at the begining of this year (Mar25) was €1,425.0 Mil.
Long-Term Debt & Capital Lease Obligation was €0.7 Mil.
Total Current Assets was €767.6 Mil.
Total Current Liabilities was €355.1 Mil.
Net Income was 34.625 + 18.608 + 186.978 + 47.753 = €288.0 Mil.

Revenue was 240.635 + 209.613 + 222.436 + 185.694 = €858.4 Mil.
Gross Profit was 115.841 + 97.78 + 101.421 + 137.147 = €452.2 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1411.73 + 1523.995 + 1396.77 + 1412.507 + 1425.004) / 5 = €1434.0012 Mil.
Total Assets at the begining of last year (Mar24) was €1,411.7 Mil.
Long-Term Debt & Capital Lease Obligation was €0.6 Mil.
Total Current Assets was €726.9 Mil.
Total Current Liabilities was €363.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin Pharmaceutical Da Ren Tang Group's current Net Income (TTM) was 265.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin Pharmaceutical Da Ren Tang Group's current Cash Flow from Operations (TTM) was 65.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=265.045/1425.004
=0.18599597

ROA (Last Year)=Net Income/Total Assets (Mar24)
=287.964/1411.73
=0.20397951

Tianjin Pharmaceutical Da Ren Tang Group's return on assets of this year was 0.18599597. Tianjin Pharmaceutical Da Ren Tang Group's return on assets of last year was 0.20397951. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tianjin Pharmaceutical Da Ren Tang Group's current Net Income (TTM) was 265.0. Tianjin Pharmaceutical Da Ren Tang Group's current Cash Flow from Operations (TTM) was 65.5. ==> 65.5 <= 265.0 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.741/1417.9556
=0.00052258

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.552/1434.0012
=0.00038494

Tianjin Pharmaceutical Da Ren Tang Group's gearing of this year was 0.00052258. Tianjin Pharmaceutical Da Ren Tang Group's gearing of last year was 0.00038494. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=767.562/355.065
=2.16175067

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=726.851/363.301
=2.00068538

Tianjin Pharmaceutical Da Ren Tang Group's current ratio of this year was 2.16175067. Tianjin Pharmaceutical Da Ren Tang Group's current ratio of last year was 2.00068538. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tianjin Pharmaceutical Da Ren Tang Group's number of shares in issue this year was 770.551. Tianjin Pharmaceutical Da Ren Tang Group's number of shares in issue last year was 763.771. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=457.064/607.66
=0.75217062

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=452.189/858.378
=0.52679472

Tianjin Pharmaceutical Da Ren Tang Group's gross margin of this year was 0.75217062. Tianjin Pharmaceutical Da Ren Tang Group's gross margin of last year was 0.52679472. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=607.66/1425.004
=0.42642687

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=858.378/1411.73
=0.6080327

Tianjin Pharmaceutical Da Ren Tang Group's asset turnover of this year was 0.42642687. Tianjin Pharmaceutical Da Ren Tang Group's asset turnover of last year was 0.6080327. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin Pharmaceutical Da Ren Tang Group has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Piotroski F-Score of 4 as of Jul. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #602 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Tianjin Pharmaceutical Da Ren Tang Group's value of 4 is 20% below this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #602 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #602 out of 981 companies for Piotroski F-Score. This places Tianjin Pharmaceutical Da Ren Tang Group in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Tianjin Pharmaceutical Da Ren Tang Group's value of 4 is 20% below this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Tianjin Pharmaceutical Da Ren Tang Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.44 — trading 48.8% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Piotroski F-Score is 4 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of €2.44 is trading 48.8% above its estimated GF Value™ of €1.64. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for STU:2TZ:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: €1.64 vs. price of €2.44 (48.8% above fair value)
  • GF Score™: 72/100 with 5 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#602 of 981)

No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore600329:China
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
72GF Score

Get the complete analysis for STU:2TZ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€1.64
GF Value